Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

BTG plc Add to portfolio

LON250:BTG, Oct 23, 08:08 UTC

Latest LON250:BTG News

Filter your feed

Apply Filter

Sunday, October 14


News

Were Analysts Bearish BTG plc (LON:BTG) This Week?

BTG

BTG PLC had 37 analyst reports since May 15, 2018 according to SRatingsIntel. As per Tuesday, August 21, the company rating was maintained by JP Morgan. 05/10/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 650.00 Maintain04/10/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 840.00 Maintain04/10/2018 Broker: Shore Capital Rating: Buy Old Target: GBX 665.00 Maintain04/10/2018 Broker: RBC Capital Markets Rating: Underperform Old Target: GBX 510.00 Maintain03/10/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 640.00 Maintain24/09/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 645.00 Maintain17/09/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 645.00 Maintain07/09/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 840.00 Maintain07/09/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 640.00 Maintain07/09/2018 Broker: Shore Capital Rating: Buy Maintain. The stock increased 3.02% or GBX 16.5 during the last trading session, reaching GBX 562. BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, October 04


Social Chatter
Social Chatter

BTG plc (LON250:BTG) social chatter is higher than usual

BTG
#FTSE250 early risers: Ferrexpo (+8.44%), BTG (+5.18%), Equiniti Group (+4.68%), Just Group (+3.81%) and Electrocomponents (+3.73%)
News

BTG upgrades full-year sales forecasts following strong portfolio performance in first half

BTG

The FTSE 250 healthcare firm said that following the incorporation of Varithena, a varicose veins treatment, into its Vascular portfolio it was upgrading its product sales forecasts for the combined Vascular and Oncology portfolios to 15%-17% growth for the year on a constant currency basis.READ: BTG snaps up medical device maker Novate for up to US$150mln. In a separate announcement, BTG also said Garry Watts, its chairman and non-executive director, would retire from his position at the end of the year. In early trading Thursday, BTG shares were up 3.1% at 577p. One year on, new boss is spearheading turnaround at drug discovery firm e-therapeutics.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, September 10


News

BTG PLC (LON:BTG) Shareholders Are Liking The News That Shore Capital Has Reiterated Their "Buy" Rating on the Stock

BTG

Among 7 analysts covering Btg (LON:BTG), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. The rating was maintained by Numis Securities with “Buy” on Friday, June 8. As per Friday, September 7, the company rating was maintained by Numis Securities. BTG plc (LON:BTG) has 0.00% since September 10, 2017 and is . After $0.05 actual earnings per share reported by BTG plc for the previous quarter, Wall Street now forecasts -20.00 % negative EPS growth.

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Friday, September 07


Social Chatter

BTG plc (LON250:BTG) social chatter is higher than usual

BTG
BTG plc Announces Acquisition of Novate Medical Ltd.: Novate Medical is a device company focused on the preventio… https://t.co/vjx0GcjjBL
News

BTG snaps up medical device maker Novate for up to US$150mln

BTG

Novate has developed Sentry, a vascular device designed to manage blood clots, which was recently deemed safe and effective by US regulators. Specialist healthcare company BTG PLC (LON:BTG) has acquired medical device maker Novate Medical in a deal which could be worth up to US$150mln. BTG plans to launch the device in the US in the second half of its financial year and will sell it through its existing vascular sales force. BTG has paid US$20mln upfront for Novate, although it may have to pay another US$130mln further down the line if certain milestones are met.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

British healthcare firm BTG buys U.S. vascular device maker

BTG

British healthcare firm BTG buys U.S. vascular device maker. (Reuters) - British healthcare company BTG Plc has acquired U.S. medical device maker Novate Medical, adding to its portfolio a vascular device for managing blood clots. BTG has paid $20 million in cash to buy Novate, and may pay a further $130 million depending on the device hitting certain sales-related milestones, the UK company said on Friday. The device, Sentry, received approval recently in the United States for use as in implant to prevent blood clots in leg veins from travelling to the lungs.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, August 01


News

Investor Outlook: BTG PLC (LON:BTG) "Hold" Rating Reconfirmed at Peel Hunt Today

BTG

This Morning, Wednesday, 1 August, BTG PLC (LON:BTG)‘s “Hold” rating was reiterated at Peel Hunt in a report. Among 7 analysts covering Btg (LON:BTG), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Btg had 26 analyst reports since March 26, 2018 according to SRatingsIntel. After $0.06 actual EPS reported by BTG plc for the previous quarter, Wall Street now forecasts -16.67 % negative EPS growth.

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Wednesday, July 18


News

BTG PLC (LON:BTG) Shareholders Are Liking The News That Shore Capital Has Reiterated Their Buy Rating on the Stock

BTG

BTG PLC (LON:BTG) Shareholders Are Liking The News That Numis Has Reiterated Their Buy Rating on the Stock. Among 7 analysts covering BTG PLC (LON:BTG), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. BTG PLC had 27 analyst reports since January 24, 2018 according to SRatingsIntel. After $0.06 actual EPS reported by BTG plc for the previous quarter, Wall Street now forecasts -16.67 % negative EPS growth.

Read Full Details

Topics:
  • Business
  • Health
  • Financial